AuraSandbox
ScreenerSectorsLearnMethodDesign
Search companies...
CtrlK
Request access
AuraSandbox
ScreenerSectorsLearnMethodDesign
Search companies...
CtrlK
Request access
Back to screenerCompare

ALKEM — ALKEM LABORATORIES LTD.

Price History

Data as of 26 Jun 2026· via fincrux

How ALKEM has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Middle of its 12-month range64% of range

Sitting roughly mid-way between its 12-month high and low — neither cheap nor stretched versus its own recent history. It sits below its 200-day average, the longer-term trend.

₹4,687 low₹5,843 high
vs 50-day avg
+0.0%
vs 200-day avg
−1.3%
Beginner mode
Plain English, with everything explained

ALKEM

NSE

ALKEM LABORATORIES LTD.

Healthcare / Pharma

₹5,425.00
0.00%
last close
0%
Quality Score
Looks high-qualityBig money steady

ALKEM LABORATORIES LTD. clears 3 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹64248.00 Cr
Price tag
27.9×
Money it earns
17.5%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.04goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 17.5%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Aligned

Professional investors have been holding steady or buying more — a quiet vote of confidence.

FII+DII 31.5%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Re…
Data as of 26 Jun 2026· via fincrux

Aura is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What ALKEM owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings2,2941,1821,005439611
Equity Capital2424242424
Reserves8,7209,32610,53112,29813,975
Total Assets13,16912,73114,03815,59617,261
Total Liabilities13,16912,73114,03815,59617,261

Borrowings trending down

Total borrowings are down about 73% over the last 5 years — the company has been reducing its reliance on debt.

Periodic Performance

Yearly net profit for ALKEM — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹1,541 Cr
₹1,134 Cr
₹1,747 Cr
₹2,281 Cr
₹2,282 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹8,830 Crrev ₹9,055 Crrev ₹7,964 Crrev ₹8,813 Crrev ₹9,664 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about ALKEM — observations, not recommendations.

Strengths

4
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Large professional investors have been holding steady or adding to their stake.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.

Risks

0

No notable risks flagged by the numbers right now.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
10.2%+1.0 pp
DII· Domestic institutions
21.4%-0.4 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
  • LAURUSLABSLAURUS LABS LIMITED100
View the full sector